Erectile dysfunction (ED) is a complex condition affecting men worldwide. Diabetes mellitus (DM) is one of the most common causes of ED. The prevalence of ED in DM varies around 35-85%. Recently, stem cell therapy has started to become the focus of experimental and clinical studies for the treatment of ED. Stem cells have been shown to be able to regenerate functionally damaged tissue, depending on the stimuli or signals received. Stem cells studies in experimental animals have been carried out using biomarker parameters, including VEGF, Bcl-2, E-selectin, cGMP, eNOS and have been shown to be successful in increasing cell survival and angiogenesis, stimulating antiapoptotic, proneurogenic, proinflammatory, and antifibrotic effects and improvements to these biomarker parameters. This study aims to determine the efficacy, mechanism of action, and safety of umbilical cord mesenchymal stem cells as a therapy for ED due to type 2 diabetes in human.
Age range
18 Years – 65 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Changes in IIEF-5 Score after stem cells injection
Timeframe: The questionnaire will be completed at baseline, 1st month, and 3rd month
Changes in Peak Systolic Velocity (PSV) after stem cells injection
Timeframe: The evaluation will be completed at baseline, 1st month, and 3rd month
Changes in End Diastolic Velocity after stem cells injection
Timeframe: The evaluation will be completed at baseline, 1st month, and 3rd month
Changes in Resistive Index after stem cells injection
Timeframe: The evaluation will be completed at baseline, 1st month, and 3rd month
Changes in Pulsatility Index after stem cells injection
Timeframe: The evaluation will be completed at baseline, 1st month, and 3rd month
Changes in E-selectin expression after stem cells injection
Timeframe: The evaluation will be completed at baseline, 1st month, and 3rd month
Changes in Vascular Endothelial Growth Factor (VEGF) expression after stem cells injection
Timeframe: The evaluation will be completed at baseline, 1st month, and 3rd month
Changes in Bcl-2 expression after stem cells injection
Timeframe: The evaluation will be completed at baseline, 1st month, and 3rd month
Changes in microRNA 16 expression after stem cells injection
Timeframe: The evaluation will be completed at baseline, 1st month, and 3rd month
Changes in microRNA 126 expression after stem cells injection
Timeframe: The evaluation will be completed at baseline, 1st month, and 3rd month